

**Amendments to the Claims**

The currently pending claims are below. Please amend the claims following, wherein the deleted matter is shown by strikethrough and the added matter is shown by underlining. This listing of claims replaces all prior versions, and listings of claims in the application.

1. (Currently amended) An isolated anti-angiogenic peptide substantially identical to 133 about 10 to about 150 consecutive amino acids of selected from the N-terminal end of human placental lactogen, human growth hormone, or growth hormone variant hGH-V, wherein the peptide inhibits angiogenesis.
  - (i) inhibits capillary endothelial cell proliferation and organization;
  - (ii) inhibits angiogenesis in chick chorioallantoic membrane; and
  - (iii) binds to at least one specific receptor which does not bind an intact full length growth hormone, placental lactogen, or growth hormone variant hGH-V.
2. (Currently amended) The isolated peptide of claim 1, wherein the isolated peptide is generated by enzymatic cleavage of growth hormone, placental lactogen, or growth hormone variant hGH-V.
3. (Canceled)
4. (Currently amended) The isolated peptide of claim 1 having the amino acid sequence of SEQ ID NO: 24.
5. (Canceled)
6. (Canceled)
7. (Canceled)

U.S. Serial No.: 10/714,067

Title: "Novel Antiangiogenic Peptide Agents and Their Therapeutic and Diagnostic Use"

Filed: November 14, 2003

Response to Office Action of July 11, 2006

Page 4 of 13

8. (Canceled)

9. (Canceled)

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Withdrawn, Currently amended) A method of treating an angiogenic disease in a subject, the method comprising administering to a subject in need of such treatment an angiogenesis inhibitory effective amount of the isolated a peptide of claim 1.

22. (Withdrawn, Currently amended) The method of claim 21, wherein the isolated peptide has the amino acid sequence of SEQ ID NO:18, SEQ ID NO:24 or SEQ ID NO:30.

23. (Withdrawn, Currently amended) A method of inhibiting tumor formation or growth in a patient, the method comprising administering to the patient an angiogenesis inhibitory effective amount of the isolated peptide of claim 1.

24. (Withdrawn, Currently amended) The method of claim 23, wherein the isolated peptide has the amino acid sequence of SEQ ID NO:18, SEQ ID NO:24 or SEQ ID NO:30.

25. (Canceled)

26. (Withdrawn, Currently amended) A method of modulating vascularization of a patient's placenta, the method comprising administering to the patient an angiogenesis inhibitory effective amount of the isolated peptide of claim 1.

27. (Currently amended) A pharmaceutical formulation, comprising comprises:  
a pharmaceutically acceptable carrier; and  
a therapeutically effective amount of an isolated a peptide as shown in chosen from SEQ ID NO:18; SEQ ID NO:24; and SEQ ID NO:30.

28. (Withdrawn) A method of treating, comprising:  
diagnosing a patient as having a tumor; and  
administering to the patient an angiogenesis inhibitory effective amount of the formulation of claim 27.

29. (New) The isolated anti-angiogenic peptide of Claim 1, wherein the anti-angiogenic peptide inhibits capillary endothelial cell proliferation and organization; inhibits angiogenesis in chick chorioallantoic membrane; and binds to at least one specific receptor which does not bind an intact full length growth hormone.

30. (New) An isolated anti-angiogenic peptide, wherein the isolated anti-angiogenic peptide is at least 95% identical to the sequence of SEQ ID NO:24, and wherein the peptide inhibits angiogenesis.

U.S. Serial No.: 10/714,067

Title: "Novel Antiangiogenic Peptide Agents and Their Therapeutic and Diagnostic Use"

Filed: November 14, 2003

Response to Office Action of July 11, 2006

Page 6 of 13

31. (New) The isolated anti-angiogenic peptide of Claim 30, wherein the isolated anti-angiogenic peptide inhibits capillary endothelial cell proliferation and organization; inhibits angiogenesis in chick chorioallantoic membrane; and binds to at least one specific receptor which does not bind an intact full length growth hormone.

32. (New) A pharmaceutical formulation, comprising:

a pharmaceutically acceptable carrier; and

a therapeutically effective amount of an isolated peptide that is at least 95% identical to the sequence of SEQ ID NO:24 and that inhibits angiogenesis.